ESR1 mutations: a new biomarker in breast cancer

Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer

(2018) R J Hartmaier et al.   ANNALS OF ONCOLOGY

4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

(2018) F Cardoso et al.   ANNALS OF ONCOLOGY

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

(2018) Rinath Jeselsohn et al.   CANCER CELL

Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines

(2018) L. Gelsomino et al.   CANCER LETTERS

Acquired resistance to aromatase inhibitors: where we stand!

(2018) Tiago Vieira Augusto et al.   ENDOCRINE-RELATED CANCER

Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer

(2018) Takashi Takeshita et al.   Molecular Cancer

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes

(2018) Shanhang Jia et al.   ONCOLOGY

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

(2018) Ben O’Leary et al.   Nature Communications

The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer

(2018) Sasha M. Pejerrey et al.   Hormones & Cancer

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial

(2018) Ben O'Leary et al.   Cancer Discovery

Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer

(2018) Jonathan T. Lei et al.   Cell Reports

Clinical value of circulating ESR1 mutations for patients with metastatic breast cancer: a meta-analysis

(2018) Kai Zhang et al.   Cancer Management and Research

The SERM/SERD bazedoxifene disrupts ESR1 helix 12 to overcome acquired hormone resistance in breast cancer cells

(2018) Sean W Fanning et al.   eLife

The global burden of women’s cancers: a grand challenge in global health

(2017) Ophira Ginsburg et al.   LANCET

Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients

(2017) Nick Beije et al.   Molecular Oncology

Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients

(2017) Takashi Takeshita et al.   Translational Oncology

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling

(2016) Luca Gelsomino et al.   BREAST CANCER RESEARCH AND TREATMENT

Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications

(2016) Jamunarani Veeraraghavan et al.   BREAST CANCER RESEARCH AND TREATMENT

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models

(2016) H. M. Weir et al.   CANCER RESEARCH

Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts

(2016) Jacqueline A. Shaw et al.   CLINICAL CANCER RESEARCH

Next Generation Sequencing of Circulating Cell-Free DNA for Evaluating Mutations and Gene Amplification in Metastatic Breast Cancer

(2016) Karen Page et al.   CLINICAL CHEMISTRY

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

(2016) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and –resistant breast cancer cells

(2016) Hei Jason Chan et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer

(2016) A Harrod et al.   ONCOGENE

Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer

(2016) Sarah Hrebien et al.   PLoS One

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

(2016) Jill M. Spoerke et al.   Nature Communications

ActivatingESR1Mutations Differentially Affect the Efficacy of ER Antagonists

(2016) Weiyi Toy et al.   Cancer Discovery

Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

(2016) Florian Clatot et al.   Oncotarget

Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole

(2016) Rekha Gyanchandani et al.   Oncotarget

Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients

(2016) Takashi Takeshita et al.   Oncotarget

Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis

(2016) Celine Lefebvre et al.   PLOS MEDICINE

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

(2016) Sean W Fanning et al.   eLife

Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer

(2016) Sarat Chandarlapaty et al.   JAMA Oncology

Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects

(2015) Yoko Omoto et al.   CANCER SCIENCE

ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients

(2015) D. Chu et al.   CLINICAL CANCER RESEARCH

Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients

(2015) P. Wang et al.   CLINICAL CANCER RESEARCH

Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer

(2015) D. S. Guttery et al.   CLINICAL CHEMISTRY

Short report: MonitoringESR1mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer

(2015) David Sefrioui et al.   INTERNATIONAL JOURNAL OF CANCER

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

(2015) Rinath Jeselsohn et al.   Nature Reviews Clinical Oncology

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer

(2015) Gaia Schiavon et al.   Science Translational Medicine

Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens

(2015) Takashi Takeshita et al.   Translational Research

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients

(2015) Jiaxin Niu et al.   OncoTargets and Therapy

Bufalin Is a Potent Small-Molecule Inhibitor of the Steroid Receptor Coactivators SRC-3 and SRC-1

(2014) Y. Wang et al.   CANCER RESEARCH

Emergence of Constitutively Active Estrogen Receptor-  Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer

(2014) R. Jeselsohn et al.   CLINICAL CANCER RESEARCH

Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

(2014) M. Yu et al.   SCIENCE

D538G Mutation in Estrogen Receptor- : A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer

(2013) K. Merenbakh-Lamin et al.   CANCER RESEARCH

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

(2013) Weiyi Toy et al.   NATURE GENETICS

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

(2013) Dan R Robinson et al.   NATURE GENETICS

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

(2013) Shunqiang Li et al.   Cell Reports

Estrogen receptor α geneESR1amplification may predict endocrine therapy responsiveness in breast cancer patients

(2009) Saori Tomita et al.   CANCER SCIENCE

Absence of ESR1 amplification in a series of breast cancers

(2008) José Adélaïde et al.   INTERNATIONAL JOURNAL OF CANCER